Inhouse production of 161Tb

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68407700%3A21340%2F24%3A00378185" target="_blank" >RIV/68407700:21340/24:00378185 - isvavai.cz</a>

Výsledek na webu

<a href="https://events.ncbj.gov.pl/event/322/attachments/601/976/Book_of_abstracts.pdf" target="_blank" >https://events.ncbj.gov.pl/event/322/attachments/601/976/Book_of_abstracts.pdf</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Inhouse production of 161Tb

Popis výsledku v původním jazyce

Terbium-161 is a promising theragnostic nuclide that offers low energy and Auger-Meitner electron emissions with low energy gamma rays for SPECT imaging. It could fill the gap between the powerful and more toxic 225Ac, and currently used beta emitter, the 177Lu. Due to scarsity of the enriched 160Gd tagert material its availability is limited. We report here the inhouse production of 161Tb using the 160Gd(n,γ)161Gd -> 161Tb reactions sequence leading to a product suitable for preclinical and potentially clinical trials. Production and possible further developments will be discussed in the presentation, including enriched 160Gd target preparation, its irradiation in a nuclear reactor, Gd/Tb separation, Tb product purification and formulation, enriched Gd recycling and labelling tests with the prepared 161Tb. Up today, some 20 production runs were performed in our laboratory resulting in an overal 161Tb activity sum of AEOB = 150 GBq. Final product activities ranged up to AEOB = 22 GBq per batch, resulting in high-purity 161Tb of radionuclidic purity over 99,999 % and a mass specific activity in the range of am(Tb) = 1,9 – 4 GBq/μg. An outlook to possible regular 161Tb production in the Czech Republic is given with a discussion on future 161Tb developments.

Název v anglickém jazyce

Inhouse production of 161Tb

Popis výsledku anglicky

Terbium-161 is a promising theragnostic nuclide that offers low energy and Auger-Meitner electron emissions with low energy gamma rays for SPECT imaging. It could fill the gap between the powerful and more toxic 225Ac, and currently used beta emitter, the 177Lu. Due to scarsity of the enriched 160Gd tagert material its availability is limited. We report here the inhouse production of 161Tb using the 160Gd(n,γ)161Gd -> 161Tb reactions sequence leading to a product suitable for preclinical and potentially clinical trials. Production and possible further developments will be discussed in the presentation, including enriched 160Gd target preparation, its irradiation in a nuclear reactor, Gd/Tb separation, Tb product purification and formulation, enriched Gd recycling and labelling tests with the prepared 161Tb. Up today, some 20 production runs were performed in our laboratory resulting in an overal 161Tb activity sum of AEOB = 150 GBq. Final product activities ranged up to AEOB = 22 GBq per batch, resulting in high-purity 161Tb of radionuclidic purity over 99,999 % and a mass specific activity in the range of am(Tb) = 1,9 – 4 GBq/μg. An outlook to possible regular 161Tb production in the Czech Republic is given with a discussion on future 161Tb developments.

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

10402 - Inorganic and nuclear chemistry

Projekt

<a href="/cs/project/TO01000074" target="_blank" >TO01000074: Účinná terapie nádorových onemocnění nízkoenergetickými elektrony terbia-161.</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů